In the October – December 2012 edition of Corporate Disputes, Brian Daniel discusses intellectual property disputes. In this roundtable discussion, the panel experts describe the underlying causes of recent disputes and key considerations of dealing with them.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...